Novel Max Binders Modulators of Myc-Mediated Transcription with Potential Use for Cancer Therapy
Invention type: Technology
/
Case number: #18257
This invention provides compounds of MAX binders and/or modulators of Myc, Mad, or Mxi1 (e.g., inhibitors of Myc, Mad, or Mxi1), which may be useful in treating a subject with a disease associated with Myc, such as proliferative diseases (e.g., cancer).
Researchers
Angela Koehler
/ Eric Stefan
/ Francisco Caballero Gonzalez
/ Dylan Neel
/ Helen Evans
/ Nicholas Struntz
/ Andrew Chen
Departments: Department of Biological Engineering, Health Sciences & Technology
Technology Areas: Biotechnology: Biomanufacturing, Biomedical Devices & Systems / Therapeutics: Cell Based Therapy
Impact Areas: Healthy Living, Advanced Materials
-
max binders as myc modulators and uses thereof
United States of America | Granted | 10,106,555 -
max binders as myc modulators and uses thereof
United States of America | Granted | 10,865,213
License this technology
Interested in this technology? Connect with our experienced licensing team to initiate the process.
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.